Implantable device for delivery of therapeutic agents
    4.
    发明申请
    Implantable device for delivery of therapeutic agents 审中-公开
    用于递送治疗剂的植入式装置

    公开(公告)号:US20080057100A1

    公开(公告)日:2008-03-06

    申请号:US11978047

    申请日:2007-10-25

    IPC分类号: A61F2/02 A61K35/12

    CPC分类号: A61N1/05 A61N1/057 A61N1/375

    摘要: A percutaneously implantable device for the treatment of a cardiac condition or other disease is disclosed herein, the device capable of delivery and maintenance of a therapeutic scaffold. A therapeutic scaffold may comprise viable tissue to impart or restore normal cardiac function, or other therapeutic agent for the treatment of disease or injury. Viable tissue may comprise a pacemaker gene or other genes intended to impart a pacemaker function to either host tissue or transplanted tissue, or both. Further, a device according to the invention may be used for the implantation and maintenance of viable tissue to induce or enhance muscle contraction of a subject for the treatment of a disease or disorder.

    摘要翻译: 本文公开了一种用于治疗心脏病或其他疾病的经皮植入装置,该装置能够递送和维持治疗性支架。 治疗性支架可以包括赋予或恢复正常心脏功能的活组织,或用于治疗疾病或损伤的其它治疗剂。 可行的组织可以包括起搏器基因或旨在赋予宿主组织或移植组织或两者的起搏器功能的其它基因。 此外,根据本发明的装置可用于植入和维持活组织以诱导或增强受试者用于治疗疾病或病症的肌肉收缩。

    Method and agent for treating vulnerable plaque
    5.
    发明申请
    Method and agent for treating vulnerable plaque 审中-公开
    治疗易损斑块的方法和药剂

    公开(公告)号:US20050260157A1

    公开(公告)日:2005-11-24

    申请号:US10531851

    申请日:2003-09-16

    IPC分类号: A61K48/00 C12N15/86

    摘要: A method and gene therapy agent for treating a vulnerable plaque associated with a blood vessel of a patient is disclosed. The method includes providing at least one gene therapy agent encoding at least one protein. The gene therapy agent is administered to a target cell population. The protein is expressed within the patient from a portion of the target cell population. The vulnerable plaque is modified as a result of the protein expression. The gene therapy agent includes at least one polynucleic acid encoding at least one protein. Administration of the gene therapy agent to a target cell population results in expression of the protein capable of modifying the vulnerable plaque.

    摘要翻译: 公开了一种用于治疗与患者血管相关的易损斑块的方法和基因治疗剂。 该方法包括提供编码至少一种蛋白质的至少一种基因治疗剂。 将基因治疗剂施用于靶细胞群体。 蛋白质在靶细胞群体的一部分内在患者体内表达。 由于蛋白质表达,脆性斑块被修饰。 基因治疗剂包括编码至少一种蛋白质的至少一种多核酸。 将基因治疗剂施用于靶细胞群体导致能够修饰易损斑块的蛋白质的表达。

    Use of endothelin antagonists to prevent restenosis
    6.
    发明申请
    Use of endothelin antagonists to prevent restenosis 审中-公开
    使用内皮素拮抗剂预防再狭窄

    公开(公告)号:US20050175667A1

    公开(公告)日:2005-08-11

    申请号:US11054009

    申请日:2005-02-08

    申请人: Wenda Carlyle

    发明人: Wenda Carlyle

    摘要: Provided are devices and methods for treating or preventing smooth muscle cell proliferation caused by endothelin-mediated conditions. In particular, a medical device comprising a structure which is implantable within a body lumen and means on or within the structure for releasing an endothelin (A) receptor antagonist at a rate effective to inhibit smooth muscle cell proliferation. The device can be, for example, an expansible stent or a graft, and the means can include a matrix coating, wherein the endothelin (A) receptor antagonist can be dispersed within the coating or disposed directly on the structure and under the matrix. The methods and devices of this invention can be used to decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.

    摘要翻译: 提供用于治疗或预防由内皮素介导的病症引起的平滑肌细胞增殖的装置和方法。 特别地,一种医疗装置,其包括可植入体腔内的结构,以及用于以有效抑制平滑肌细胞增殖的速率释放内皮素(A)受体拮抗剂的结构上或内部的装置。 该装置可以是例如可扩张支架或移植物,并且该装置可以包括基质涂层,其中内皮素(A)受体拮抗剂可以分散在涂层内或直接设置在结构上和在基质之下。 本发明的方法和装置可用于降低再狭窄的发生率以及由植入医疗装置引起的其它血栓栓塞并发症。

    Gradient coated stent and method of fabrication
    7.
    发明申请
    Gradient coated stent and method of fabrication 有权
    梯度涂层支架及其制造方法

    公开(公告)号:US20050075714A1

    公开(公告)日:2005-04-07

    申请号:US10921735

    申请日:2004-08-18

    摘要: The gradient coated stent 150 of the present invention provides a coated stent having a continuous coating 130 disposed on the stent elements. The continuous coating 130 includes a first coating component and a second coating component. The concentration of the first coating component varies continuously over at least part of the thickness of the continuous coating 130. The concentration of the second coating component can also vary over at least part of the thickness of the continuous coating 130. In one embodiment, the concentration of the first coating component decreases in the direction from the stent element towards the outer edge of the continuous coating 130 and the concentration of the second coating component increases in the direction from the stent element towards the outer edge of the continuous coating 130.

    摘要翻译: 本发明的梯度涂层支架150提供了涂层支架,其具有设置在支架元件上的连续涂层130。 连续涂层130包括第一涂层组分和第二涂层组分。 第一涂层组分的浓度在连续涂层130的厚度的至少一部分上连续变化。第二涂层组分的浓度也可以在连续涂层130的至少一部分厚度上变化。在一个实施方案中, 第一涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上减小,并且第二涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上增加。

    Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
    9.
    发明申请
    Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis 审中-公开
    包含抑制再狭窄的蛋白质 - 酪氨酸激酶抑制剂的医学装置

    公开(公告)号:US20050214343A1

    公开(公告)日:2005-09-29

    申请号:US10490248

    申请日:2003-07-17

    IPC分类号: A61F2/00 A61F2/86 A61K31/506

    摘要: Implantable medical devices having an anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of proteintyrosine kinase inhibitors are disclosed. The anti-restenotic protein-tyrosine kinase inhibitor is 4+4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and pharmaceutically acceptable derivatives thereof (imatinib mesylate). The anti-restenotic medial devices include stents, catheters, micro-particles, probes and vascular grafts. The medical devices can be coated using any method known in the art including compounding the protein-tyrosine kinase inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-protein-tyrosine kinase inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one proteintyrosine kinase inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the antirestenotic implantable devices are also disclosed.

    摘要翻译: 公开了具有抗再狭窄涂层的植入式医疗装置。 具体地,公开了具有蛋白酪氨酸激酶抑制剂的涂层的可植入医疗装置。 抗再狭窄蛋白酪氨酸激酶抑制剂是4 + 4-甲基-1-哌嗪基)甲基] -N- [4-甲基-3 - [[4-(3-吡啶基)-2-嘧啶基]氨基] - 苯基]苯甲酰胺 甲磺酸盐及其药学上可接受的衍生物(甲磺酸伊马替尼)。 抗再狭窄的内侧装置包括支架,导管,微粒,探针和血管移植物。 医疗装置可以使用本领域已知的任何方法进行包衣,包括在施加涂层之前将蛋白质 - 酪氨酸激酶抑制剂与生物相容性聚合物混合。 此外,公开了完全由生物相容性聚合物 - 蛋​​白 - 酪氨酸激酶抑制剂共混物组成的医疗装置。 此外,还公开了具有包含至少一种蛋白酪氨酸激酶抑制剂与至少一种另外的治疗剂组合的包衣的医疗装置。 此外,还公开了使用和制造抗再狭窄植入式装置的相关方法。

    Gradient coated stent and method of fabrication
    10.
    发明授权
    Gradient coated stent and method of fabrication 有权
    梯度涂层支架及其制造方法

    公开(公告)号:US08801692B2

    公开(公告)日:2014-08-12

    申请号:US10921735

    申请日:2004-08-18

    IPC分类号: A61M31/00 A61F2/06 A61L33/00

    摘要: The gradient coated stent 150 of the present invention provides a coated stent having a continuous coating 130 disposed on the stent elements. The continuous coating 130 includes a first coating component and a second coating component. The concentration of the first coating component varies continuously over at least part of the thickness of the continuous coating 130. The concentration of the second coating component can also vary over at least part of the thickness of the continuous coating 130. In one embodiment, the concentration of the first coating component decreases in the direction from the stent element towards the outer edge of the continuous coating 130 and the concentration of the second coating component increases in the direction from the stent element towards the outer edge of the continuous coating 130.

    摘要翻译: 本发明的梯度涂层支架150提供了涂层支架,其具有设置在支架元件上的连续涂层130。 连续涂层130包括第一涂层组分和第二涂层组分。 第一涂层组分的浓度在连续涂层130的厚度的至少一部分上连续变化。第二涂层组分的浓度也可以在连续涂层130的至少一部分厚度上变化。在一个实施方案中, 第一涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上减小,并且第二涂层组分的浓度在从支架元件朝向连续涂层130的外边缘的方向上增加。